
An International Publisher for Academic and Scientific Journals
Author Login
SAS Journal of Medicine | Volume-11 | Issue-04
Initiating Opioid Substitution Treatment: A Comprehensive Guide for General Practitioners
Dr Imran Malik, Dr Usman Ashfaq
Published: April 4, 2025 |
77
54
Pages: 265-271
Downloads
Abstract
The article "Initiating Opioid Substitution Treatment: A Comprehensive Guide for General Practitioners" is a review intended to guide GPs in managing opioid dependence using opioid substitution treatment (OST). OST, which primarily involves methadone and buprenorphine, aims to help patients achieve stability and recovery by substituting illicit opioids, thereby reducing withdrawal symptoms and cravings. The article stresses the multifaceted nature of drug misuse patients, emphasizing the need for a thorough assessment. This assessment should cover the patient's substance use history, medical and mental health background, current medications (paying close attention to interactions with drugs like gabapentin and pregabalin), the risk of overdose and medication diversion, collaborative treatment planning with the patient, prior treatment experiences, information from support networks, physical examination findings, and social circumstances. Initiating OST requires a credible account of recent, substantial opiate use, confirmation through drug tests, and observable withdrawal signs, potentially evaluated with the COWS score. Patient safety is paramount during the initiation phase, recommending low starting doses with gradual increases under direct observation to prevent overdose. The stabilization phase involves adjusting the dosage based on individual needs by experienced prescribers, who must distinguish between toxicity and withdrawal symptoms. Long-term maintenance includes continuous monitoring, addressing any ongoing illicit drug use, providing comprehensive psychological and social support, and collaborating with specialists when necessary. The guide also outlines important aspects of safe prescribing, the conditions under which prescriptions may be suspended or discontinued, and critical safety measures related to high-risk periods like treatment initiation and release from incarceration, potential drug interactions, preventing diversion, and managing concurrent